Background/aims: Serial Scheimpflug corneal tomography to monitor the progression of keratoconus has become standard practice in most countries where corneal cross-linking is available. The tomographic definitions of progression are, however, poorly defined. The aims of this study were: (a) to estimate the 95% limits of intraobserver and interobserver agreement of corneal shape parameters on Pentacam in patients with keratoconus and (b) to investigate whether these limits of agreement varied according to disease severity.
Methods: 96 adult patients with keratoconus and no corneal scarring or history of previous surgery were recruited from a corneal clinic in a tertiary ophthalmology hospital. One eye of each subject was scanned twice by each of the two observers with the Pentacam HR. 95% limits of intraobserver and interobserver agreement for K1, K2, Kmax and corneal thickness at the thinnest corneal location (TCT) were calculated.
Results: Reproducibility of keratometry measures was better for early keratoconus than advanced keratoconus. In patients of Pentacam-derived Krumeich stage 1 or 2, the 95% limits of interobserver agreement for Kmax were from -0.90 to 1.01. In patients of Pentacam-derived Krumeich stage >2, the 95% limits of interobserver agreement for Kmax were from -3.71 to 3.86.
Conclusions: Keratometric measurements on Pentacam HR are less reproducible in advanced keratoconus than in early keratoconus. In patients of Pentacam-derived Krumeich stage 1 or 2, an increase in K1, K2 or Kmax of more than 1 dioptre is likely to represent the real change in the corneal shape.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bjophthalmol-2015-307201 | DOI Listing |
Front Immunol
January 2025
Department of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
Background: Nivolumab paved a new way in the treatment of patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (RM-HNSCC). However, the limited rates of long-term survivors (< 20%) demand a robust prognostic biomarker. This nationwide multi-centric prospective study aimed to identify a plasma exosome (PEX) mRNA signature, which serves as a companion diagnostic of nivolumab and provides a biological clue to develop effective therapies for a majority of non-survivors.
View Article and Find Full Text PDFPak J Med Sci
January 2025
Hongyan Zhu, Hospital Infection Management Division, Shaoxing People's Hospital, Shaoxing, Zhejiang Province312000, P.R. China.
Objective: The survival benefit of venoarterial Extracorporeal Membrane Oxygenation (ECMO) for the management of acute high-risk pulmonary embolism (PE) remains unclear. This meta-analysis combines data from comparative studies to assess the risk of mortality after ECMO vs standard care in the management of acute high-risk PE.
Methods: Databases of PubMed, CENTRAL, Scopus, Web of Science, and Embase were searched from 01 January 2000 to 24 March 2023 for comparative studies with at least 10 patients/group comparing ECMO vs standard treatment.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, 6997801, Israel.
Background: The relationship between inflammatory bowel diseases (IBD) and the risk of ischemic heart diseases (IHD) remains a subject of debate. In this study, we sought to investigate the association between IBD and long-term risk of IHD in a substantial cohort of IBD patients.
Methods: In this retrospective cohort study we utilized data from a state-mandated provider in Israel (Maccabi Healthcare Services).
Crohns Colitis 360
January 2025
Division of Digestive Diseases and Nutrition, Department of Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.
Background: Despite advancements in the therapeutic armamentarium for Crohn's disease (CD), biologic and small molecule monotherapies are associated with sub-optimal response and remission rates. Utilizing dual biologic therapy (DBT) holds the potential to increase efficacy in the treatment of refractory or partially responsive CD. Evidence pertaining to this strategy remains limited.
View Article and Find Full Text PDFGlob Heart
January 2025
Spirituality and Cardiovascular Medicine Department, Brazilian Cardiology Society -DEMCA/SBC, Brasil.
Background: Emerging evidence suggests that spirituality improves patient outcomes, however, this has undergone only limited evaluation in randomized trials. Hypertension is a major cause of cardiovascular morbidity and mortality worldwide.
Objectives: To evaluate whether a spirituality-based intervention, compared to a control group, can reduce blood pressure (BP) and improve endothelial function after 12 weeks in patients with mild or moderate hypertension (HTN).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!